论文部分内容阅读
目的检测滤泡性甲状腺癌中Endoglin(又称CD105)和内皮抑素(Endostatin,ES)蛋白表达情况,探讨滤泡性甲状腺癌中血管内皮增殖与肿瘤转移侵袭的相关性。方法收集重庆市第九人民医院及中国医科大学附属第一人民医院甲状腺癌存档蜡块,包括甲状腺乳头状癌(papillary thyroid carcinoma,PTC)130例,滤泡状癌(follicular thyroid carcinoma,FTC)40例,甲状腺未分化癌(undifferentiated thyroid carcinoma,UTC)30例,制作组织芯片,采用免疫组织化学染色法检测滤泡性甲状腺癌中CD105和ES蛋白的表达情况。结果 CD105在PTC、FTC和UTC样本中的表达水平依次递增,平均IRS评分分别为6.1±0.7、7.3±0.8和10.6±1.4(P<0.01);CD105的表达水平与性别、年龄无关,而与癌灶发生甲状腺外侵袭、淋巴结转移和远处转移相关;在随访期内发生甲状腺癌复发或死亡患者的CD105表达水平较病情稳定患者明显升高(P<0.01)。ES在PTC、FTC和UTC样本中的表达水平依次递增,平均IRS评分分别为5.6±2.0、7.0±1.8和9.1±1.2(P<0.01);ES蛋白表达水平与性别、年龄无关,而与腺外侵袭、淋巴结转移或远处转移相关;在随访期内发生甲状腺癌复发或死亡患者的ES表达水平较病情稳定患者明显增高(P<0.01)。同一病例的CD105表达评分与ES表达评分呈正相关(r=0.313,P<0.01)。结论 CD105及ES在不同侵袭性的甲状腺癌组织中的表达存在差异,且具有相关性,可能参与了甲状腺癌的侵袭、转移,导致预后改变,提示其可作为甲状腺癌靶向治疗的靶点之一,为甲状腺癌的治疗提供新的研究方向。
Objective To detect the protein expression of Endoglin (also known as CD105) and endostatin (ES) in follicular thyroid carcinoma and to explore the correlation between the proliferation of vascular endothelial cells and invasion and metastasis of follicular thyroid carcinoma. Methods Thyroid cancer preserved paraffin blocks were collected from the 9th People’s Hospital of Chongqing and the First People’s Hospital Affiliated to China Medical University, including 130 cases of papillary thyroid carcinoma (PTC), 40 cases of follicular thyroid carcinoma (FTC) Thirty cases of undifferentiated thyroid carcinoma (UTC) were enrolled in this study. Tissue microarray was used to detect the expression of CD105 and ES protein in follicular thyroid carcinoma by immunohistochemical staining. Results The expression levels of CD105 in PTC, FTC and UTC samples increased gradually with the mean IRS score of 6.1 ± 0.7, 7.3 ± 0.8 and 10.6 ± 1.4, respectively (P <0.01). The expression level of CD105 was not related to gender and age, The incidence of extrathyroidal invasion, lymph node metastasis and distant metastasis were related to the foci. The expression of CD105 in patients with recurrence or death of thyroid carcinoma during the follow-up period was significantly higher than that in patients with stable disease (P <0.01). The expression of ES in PTC, FTC and UTC samples increased gradually with the average IRS score of 5.6 ± 2.0, 7.0 ± 1.8 and 9.1 ± 1.2, respectively (P <0.01). The expression of ES protein was not related to sex and age, External invasion, lymph node metastasis or distant metastasis. The ES expression in patients with recurrence or death of thyroid cancer during the follow-up period was significantly higher than that in patients with stable disease (P <0.01). The same case of CD105 expression score and ES expression score was positively correlated (r = 0.313, P <0.01). Conclusion The expressions of CD105 and ES in different invasive thyroid cancer tissues are different, and they are correlated with each other, which may be involved in the invasion and metastasis of thyroid carcinoma, which may lead to the prognosis. It suggests that CD105 and ES can be used as the target of targeted therapy in thyroid cancer First, provide a new research direction for the treatment of thyroid cancer.